Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG) - PubMed (original) (raw)
Clinical Trial
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG)
I Songun et al. Eur J Cancer. 1999 Apr.
Abstract
The aim of this trial was to investigate whether pre-operative chemotherapy leads to a 15% higher curative resectability rate in patients with operable gastric cancer. In this randomised trial, patients were allocated to receive either four courses of chemotherapy using 5-fluorouracil, doxorubicin and methotrexate (FAMTX) prior to surgery or to undergo surgery only. Patients younger than 75 years of age with a good physical and mental condition and a histologically proven adenocarcinoma of the stomach without clinical or radiographic (computed tomography scan) evidence of distant metastases were eligible for this trial. Early gastric cancer or cardia carcinoma were excluded. The response to chemotherapy was evaluated after two and four courses. In case of progressive disease (PD) after two courses, patients were operated upon as soon as possible. Otherwise complete response (CR) partial response (PR) or stable disease (SD), two more courses were scheduled. The standard surgical procedure was a limited lymphadenectomy (D1) with staging biopsy of the para-aortic lymph nodes. Between September 1993 and February 1996, 56 eligible and evaluable patients were entered: 27 were randomised to receive FAMTX before surgery and 29 to undergo surgery only. In the FAMTX + surgery treatment group, 15/27 (56%) had curative resections versus 18/29 (62%) in the surgery only arm. There was no difference in the frequency of TNM stages I + II in both treatment arms: 15/27 versus 15/29. Due to PD and/or toxicity, 12 patients (44%) could not complete the planned four courses of FAMTX. Response evaluation after chemotherapy was possible in 25 patients: 2 CR, 6 PR, 8 SD and 9 PD. The difference in curative resectability rate was 6.5% (95% confidence interval -32 to +19%) in favour of surgery only. Downstaging for stages I + II did not occur. PD was more often the reason for not completing the planned four courses than toxicity. More active regimens than FAMTX are required for future randomised trials.
Similar articles
- Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Hartgrink HH, et al. Eur J Surg Oncol. 2004 Aug;30(6):643-9. doi: 10.1016/j.ejso.2004.04.013. Eur J Surg Oncol. 2004. PMID: 15256239 Clinical Trial. - Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M. Kelsen D, et al. J Clin Oncol. 1996 Jun;14(6):1818-28. doi: 10.1200/JCO.1996.14.6.1818. J Clin Oncol. 1996. PMID: 8656250 Clinical Trial. - Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Vanhoefer U, et al. J Clin Oncol. 2000 Jul;18(14):2648-57. doi: 10.1200/JCO.2000.18.14.2648. J Clin Oncol. 2000. PMID: 10894863 Clinical Trial. - Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP. Kelsen DP. Semin Oncol. 1996 Jun;23(3):379-89. Semin Oncol. 1996. PMID: 8658222 Review. - The treatment of advanced gastric cancer.
Wils J. Wils J. Semin Oncol. 1996 Jun;23(3):397-406. Semin Oncol. 1996. PMID: 8658224 Review.
Cited by
- A decade in gastric cancer curative surgery: Evidence of progress (1999-2009).
Rausei S, Dionigi G, Rovera F, Boni L, Valerii C, Giavarini L, Frattini F, Dionigi R. Rausei S, et al. World J Gastrointest Surg. 2012 Mar 27;4(3):45-54. doi: 10.4240/wjgs.v4.i3.45. World J Gastrointest Surg. 2012. PMID: 22530078 Free PMC article. - A systematic review and network meta-analysis protocol of neoadjuvant treatments for patients with gastric cancer.
Long B, Yu ZY, Li Q, Du HR, Wang ZJ, Zhan H, Jiao ZY. Long B, et al. Medicine (Baltimore). 2018 Apr;97(15):e0392. doi: 10.1097/MD.0000000000010392. Medicine (Baltimore). 2018. PMID: 29642200 Free PMC article. - Gastric adenocarcinoma: review and considerations for future directions.
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Dicken BJ, et al. Ann Surg. 2005 Jan;241(1):27-39. doi: 10.1097/01.sla.0000149300.28588.23. Ann Surg. 2005. PMID: 15621988 Free PMC article. Review. - Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Marcus SG, et al. J Gastrointest Surg. 2003 Dec;7(8):1015-22; discussion 1023. doi: 10.1016/j.gassur.2003.09.007. J Gastrointest Surg. 2003. PMID: 14675711 - Does tumor size have an impact on gastric cancer? A single institute experience.
Jun KH, Jung H, Baek JM, Chin HM, Park WB. Jun KH, et al. Langenbecks Arch Surg. 2009 Jul;394(4):631-5. doi: 10.1007/s00423-008-0417-0. Epub 2008 Sep 13. Langenbecks Arch Surg. 2009. PMID: 18791731
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials